ArticleFocus (American Psychiatric Publishing)2021
Pharmacotherapy for Anxiety Disorders: From First-Line Options to Treatment Resistance.
Article in Focus (American Psychiatric Publishing), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Functional neuroimaging of Cannabidiol in stress and anxiety: a systematic review.Frontiers in neuroimaging · 2026Pooled it
- Joint Clinical Practice Guideline on Benzodiazepine Tapering: Considerations When Risks Outweigh Benefits.Journal of general internal medicine · 2025Guideline
- From Subjective to Objective: The Bedside Value of HRV in AssessingChronic Pain Complicated by Emotionaland Sleep Issues.Applied psychophysiology and biofeedback · 2026Article
- Cannabidiol at the crossroads: panacea, placebo, or problem?Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026Review
- Chitosan-Based Nanoparticles for Nose-to-Brain Drug Delivery: A Real Path toward Effective CNS Therapy?ACS biomaterials science & engineering · 2026Review
- Sertraline-induced bruxism: a case report and review of the literature.Journal of medical case reports · 2026Review
- Anxiety and panic disorder: First-line pharmacotherapy.Bioinformation · 2026Article
- Anxiolytic and Antidepressant-Like Effects of a Probiotic Mixture HMLH123 Potentially via the Serotonergic Pathway in Wistar Rats.Behavioural neurology · 2026Article
- Effects of app delivered self hypnosis on stress management.NPJ digital medicine · 2025Article
- Astrocytes in Rodent Anxiety-Related Behavior: Role of Calcium and Beyond.International journal of molecular sciences · 2025Review
- Gingerols and Shogaols ofJournal of experimental pharmacology · 2025Article
- Falls in a single brain rehabilitation center: a 3-year retrospective chart review.Frontiers in neurology · 2025Article
- Using Natural Language Processing to develop risk-tier specific suicide prediction models for Veterans Affairs patients.Journal of psychiatric research · 2024Article
- Reversing anxiety by targeting a stress-responsive signaling pathway.Proceedings of the National Academy of Sciences of the United States of America · 2024Article
- The state of anxiety treatments for adolescents and adults down syndrome: Results from a scoping rapid review.Journal of mood and anxiety disorders · 2024Review
- β-Carboline (FG-7142) modulates fear but not anxiety-like behaviour in zebrafish.Scientific reports · 2024Article
- Authors' Reply to Pande et al. Comment on "Extended-Release Viloxazine Compared to Atomoxetine for Attention Deficit Hyperactivity Disorder".CNS drugs · 2023Article
- Long-term use of benzodiazepines in chronic insomnia: a European perspective.Frontiers in psychiatry · 2023Article
- Experiential Avoidance as a Transdiagnostic Mediator in the Relationship Between Intolerance of Uncertainty, Maladaptive Perfectionism, and Psychiatric Symptoms: Structural and Causal Mediation Analyses in a Clinical Sample.Clinical psychology & psychotherapyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, the author examines the evidence for psychopharmacologic treatments among adults for generalized anxiety disorder, panic disorder, and social anxiety disorder derived from clinical trials. For each disorder, major categories of drugs are reviewed, and then the evidence-based medications in each category are discussed. The author reviews key safety and tolerability considerations for each of the medications or classes. Evidence-based dosing for most specific agents is displayed in a comprehensive reference table. Subsequently, the author synthesizes the available information to suggest a pragmatic stepwise approach to treatment that accounts for patient-specific factors. To inform the guidance, the author incorporates and refines perspectives from treatment guidelines already written by clinical professional organizations. The author also briefly reviews the relatively new quantitative systematic review methodology of network meta-analysis (NMA) and discusses how NMA may help guide pharmacologic treatment sequencing decisions in the future by way of ranking treatments according to effect size and the relative amount of study to which treatments have been subject. Caveats of NMA studies are briefly discussed, as are results of recent NMAs regarding the pharmacologic treatment of anxiety disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.